Chapter 37.Valproate
Sections
Excerpt
Valproate was the first mood stabilizer to be studied as an alternative to lithium (Lambert et al. 1966). An enteric-coated formulation, divalproex sodium, was approved in the United States for the treatment of mania in 1995. An extended-release (ER) formulation of divalproex was approved for migraine in 2001 and for mania in 2006. Valproate, either as divalproex or as other formulations, is now approved worldwide for the treatment of mania.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).